Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Mediwelcome Healthcare Management & Technology Cash Conversion Cycle Related Terms
Mediwelcome Healthcare Management & Technology Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02159 vs VEEV, BTSG, TEM: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, Mediwelcome Healthcare Management & Technology's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mediwelcome Healthcare Management & Technology Cash Conversion Cycle vs Healthcare Providers & Services Industry
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mediwelcome Healthcare Management & Technology (HKSE:02159) has a Cash Conversion Cycle of 0.60 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Mediwelcome Healthcare Management & Technology and its competitors.
Is Mediwelcome Healthcare Management & Technology's Cash Conversion Cycle too high?
Mediwelcome Healthcare Management & Technology's current Cash Conversion Cycle is 0.60. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.83. Mediwelcome Healthcare Management & Technology's value of 0.60 is 96.6% below this industry median. Overall, Mediwelcome Healthcare Management & Technology has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mediwelcome Healthcare Management & Technology's Cash Conversion Cycle compare to VEEV and BTSG?
Mediwelcome Healthcare Management & Technology's Cash Conversion Cycle of 0.60 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.83. Mediwelcome Healthcare Management & Technology's value of 0.60 is 96.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.83, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mediwelcome Healthcare Management & Technology's current Cash Conversion Cycle of 0.60 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mediwelcome Healthcare Management & Technology's current Cash Conversion Cycle is 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mediwelcome Healthcare Management & Technology stock overvalued right now?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology (HKSE:02159) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.70, compared to a current price of HK$1.69 — trading 141.4% above its estimated fair value. The current Cash Conversion Cycle is 0.60 and 96.6% below the Healthcare Providers & Services industry median of 17.83. Mediwelcome Healthcare Management & Technology's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Mediwelcome Healthcare Management & Technology (HKSE:02159), the current Cash Conversion Cycle is 0.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mediwelcome Healthcare Management & Technology (HKSE:02159) Overvalued in 2026?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology stock appears to be overvalued.
The current stock price of HK$1.69 is trading 141.4% above its estimated GF Value™ of HK$0.70.
GuruFocus considers Mediwelcome Healthcare Management & Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02159:
Cash Conversion Cycle: 0.60
GF Value™: HK$0.70 vs. price of HK$1.69 (141.4% above fair value)
Industry Position: 96.6% below the Healthcare Providers & Services median
No single metric tells the full story. See the HKSE:02159 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mediwelcome Healthcare Management & Technology Business Description
Mediwelcome Healthcare Management & Technology Inc is an investment holding company. The Group mainly provides medical conference services, patient education and screening services, and marketing and consulting services, in addition to providing integrated healthcare marketing solutions. Its products and services include Academic Conference Management System, Scientific Research Data Reporting System, the Health/Medical Media Matrix, patient management services, and marketing and consulting services. The Group has only one reportable segment, mainly operating its businesses in the PRC and earning revenue from the PRC.
54GF Score
Get the complete analysis for HKSE:02159
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02159 has been successfully added to your 
